KR20100018118A - Nanoemulsion for topical administration - Google Patents

Abstract

PURPOSE: A nanoemulsion for topical administration containing active ingredient is provided to promote skin permeability of aqueous ingredient, lipid ingredient and protein drug. CONSTITUTION: A nanoemulsion for topical administration contains 1-10 weight parts of oil, 5-40 weight parts of PEG-8 caprylic/capric glyceride, 0.5-10 weight parts of lecithin, 0.5-10 weight parts of skin permeable promoter and 20-90 weight parts of water. The nanoemulsion further contains ethanol, butyleneglycol, isopropylalcohol, glycerol or their mixture. The skin permeable promoter is poroxamer, polysorbate 20, nerolidol, 2-n-nonyl-1,3-dioxolane, urea, limonene, or their mixture. A method for preparing the nanoemulsion comprises: a step of dissolving lecithin in ethanol, butyleneglycol, isopropylalcohol, or glycerol to obtain lecithin solution; a step of adding PEG-8 caprylic/capric glyceride and oil to the lecithin solution to make mixture; a step of adding water to the mixture to form nanoemulsion; and a step of skin permeable promoter to the nanoemulsion.

Description

Nanoemulsion for topical administration

The present invention relates to a nanoemulsion for topical administration, a method for preparing the same, a pharmaceutical product containing the nanoemulsion, and a cosmetic containing the nanoemulsion, and more particularly, the skin absorption rate of the active ingredient when the topical administration to the skin is excellent. In addition, the nanoemulsion state is maintained when diluted in water, and only the active ingredient can be selectively penetrated compared to the preservative, and can be applied to both water-soluble and fat-soluble drugs and protein drugs, and in addition to the active ingredient, the nanoemulsion itself has a whitening effect. The present invention relates to a nanoemulsion, a method for producing the same, a pharmaceutical including the nanoemulsion, and a cosmetic containing the nanoemulsion.

Arbutin is widely known as a tyrosinase inhibitor, an enzyme involved in the oxidation process of tyrosine, and is the most widely used substance for whitening cosmetics because it is recognized as a functional whitening substance. However, this material has a problem that it is difficult to see the actual effect due to difficult skin penetration (S. Bian, MK Choi, H. Lin, J, Zheng, SJ Chung, CK Shim, DD Kim, Deformable liposomes for topical skin delivery) of arbutin.J Kor Pharm Sci. 36: 293-304, 2006). In addition, in addition to arbutin, various functional cosmetic raw materials, such as vitamin C, adenosine, botox-like peptide, pycnogenol, glucosylhesperidine, ceramide, are difficult to penetrate the skin, and thus have no practical effect.

Methotrexate (MTX) is a folic acid antagonist that is widely used in severe psoriasis, atopy and arthritis, and is known for its anticancer and immunomodulatory properties. Although it is a drug currently used as a systemic therapy for psoriasis, many efforts are being made to develop a topical psoriasis treatment through the skin to reduce the side effects. However, MTX is difficult to penetrate the skin and requires an effective transdermal absorption system to develop into a topical psoriasis treatment (M. Trotta, E. Peira, ME Carlotti, M. Gallarate, Deformable liposomes for dermal administration of methotrexate.Int J Pharma 270: 119-125, 2004). In addition to MTX, there is a need for the development of agents for promoting transdermal absorption of drugs for treating skin diseases.

As a method for promoting transdermal absorption of such functional cosmetic raw materials and medicines for treating skin diseases, a method of increasing the fat solubility of the substance itself, a method of formulating into liposomes or microemulsions, a method of applying iontoporesis, etc. are used. M. Trotta, E. Peira, ME Carlotti, M. Gallarate, Deformable liposomes for dermal administration of methotrexate.Int J Pharma. 270: 119-125, 2004; MJ Alvarez-Figueroa, MB Delgado-Charro, J. Blanco-Mendez , Passive and iontophoretic transdermalpenetration of methotrexate.Int J Pharma. 212: 101-107, 2001; MJ Alvarez-Figueroa, J. Blanco-Mendez, Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsion.Int J Pharm. 215: 57-65, 2001; DD Verma, A. Fahr, Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J Control Release, 97: 55-66, 2004; J. Guo, Q. Ping, G. Sun, C. Jiao, Lecithin vesicular carriers for transdermal delivery of cyclosporin A, Int J Pharm. 194: 201-207, 2000). However, the method of increasing the fat solubility of the substance itself is limited depending on the type of the substance, and the method of preparing lipid microspheres such as liposomes and microemulsions promotes skin permeation of the active ingredient, but it is not easy to obtain sufficient effects. In addition, the method using the iontophoresis is effective but has the disadvantage that it cannot be conveniently applied because additional equipment is required.

According to a paper on MTX skin permeation using liposomes and microemulsions, the improvement of skin permeation of MTX using these preparations has been disclosed (M. Trotta, E. Peira, ME Carlotti, M. Gallarate, Deformable liposomes for dermal administration of Int J Pharma. 270: 119-125, 2004; MJ Alvarez-Figueroa, J. Blanco-Mendez, Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsion.Int J Pharm. 215: 57-65, 2001). Such formulations are known to promote transdermal absorption but not to a degree sufficient to cause a satisfactory effect.

Therefore, there is a need for the development of a formulation capable of sufficiently improving the transdermal absorption of functional cosmetic raw materials or drugs for treating skin diseases.

Accordingly, the present inventors have endeavored to develop a formulation capable of sufficiently increasing the percutaneous absorption of functional cosmetic raw materials and drugs for treating skin diseases. As a result, the present invention includes lecithin as a co-surfactant and PEG-8 caprylic / capric glyceride as a surfactant. And the additional inclusion of a skin permeation enhancer to enable nanoemulsions to effectively permeate all water soluble substances, fat soluble substances, peptides and protein drugs through the skin, increase the stability of the drug as well as increase the stability of the formulation itself. Discovered that the present invention was completed.

Accordingly, it is an object of the present invention to provide transdermal absorption of various drugs including water soluble substances, fat soluble substances, peptides and proteins, and to provide nanoemulsions with excellent pharmaceutical properties.

Another object of the present invention is to provide a method for preparing a nanoemulsion having the excellent pharmaceutical properties.

It is another object of the present invention to provide a cosmetic or pharmaceutical product comprising the nanoemulsion having the excellent pharmaceutical properties.

In order to achieve the above object, the present invention provides 1-10 parts by weight of oil, 5-40 parts by weight of PEG-8 caprylic / capric glyceride, 0.5-10 parts by weight of lecithin, 0.5-10 parts by weight of skin permeation accelerator, And 20-90 parts by weight of water to provide an active ingredient-containing nanoemulsion for topical administration.

The topical administration nanoemulsion

Preparing a lecithin solution by dissolving lecithin in ethanol or butylene glycol;

Preparing a mixed solution by adding and mixing PEG-8 caprylic / capric glyceride and oil to the lecithin solution;

Adding water while stirring the mixture to form a nanoemulsion; And

Adding and mixing a skin permeation promoter to the nanoemulsion;

Depending on the water solubility of the active ingredient can be prepared by a method characterized by dissolving the active ingredient in the oil or water.

The present invention also provides a cosmetic comprising the nanoemulsion for topical administration.

The present invention also provides a medicament comprising the nanoemulsion for topical administration.

Hereinafter, the present invention will be described in more detail.

All technical terms used in the present invention, unless defined otherwise, are used in the meaning as commonly understood by those skilled in the art in the related field of the present invention. Also described herein are preferred methods or samples, but similar or equivalent ones are within the scope of the present invention. The contents of all publications described herein by reference are incorporated herein by reference in their entirety.

The present inventors have studied to develop a preparation capable of sufficiently increasing the percutaneous absorption of functional cosmetic raw materials such as arbutin and the like for the treatment of skin diseases such as methotrexate, and as a surfactant PEG-8 caprylic / capric glycerides as surfactants. It has been discovered that the nanoemulsion prepared by using lecithin as a cosurfactant and additionally including a skin permeation accelerator can significantly increase the percutaneous absorption of the active ingredient.

Accordingly, the present invention in one aspect, 1-10 parts by weight of oil, 5-40 parts by weight of PEG-8 caprylic / capric glycerides, 0.5-10 parts by weight of lecithin, 0.5-10 parts by weight of skin permeation accelerator, And it provides a nanoemulsion for topical administration containing the active ingredient comprising 20 to 90 parts by weight of water. Preferably, the nanoemulsion is 3-6 parts by weight of oil, 15-25 parts by weight of PEG-8 caprylic / capric glyceride, 2-4 parts by weight of lecithin, 2-4 parts by weight of skin penetration promoter, and water 30-70 parts by weight.

The topical administration nanoemulsion is preferably prepared further comprising an alcohol selected from the group consisting of ethanol, butylene glycol, isopropyl alcohol, glycerol, and combinations thereof. Such alcohols are preferred because they not only act as co-surfactants, but also promote skin penetration of the active ingredient and impart a moisturizing effect to the skin. The alcohol may be included in the nanoemulsion 5-25 parts by weight.

The oil included in the nanoemulsion is isopropyl myristate, medium chain triglycerides, hexyldecanol, cetyl caprylate, soybean oil, camellia oil, evening primrose oil, emu oil, pumpkin seed oil (Pumpkin seed oil), borage oil Borage oil or a combination thereof, but is not limited thereto, and any oil conventionally used for preparing a nanoemulsion may be used.

Lecithin included in the nanoemulsion is a kind of phospholipid, prepared by extracting from soybean or egg, or prepared by further purification, and may have a content of phosphatidylcholine of 30 to 95 wt%. Preferably, lecithin with a content of phosphatidylcholine of at least 70% by weight can be used.

The skin penetration promoter included in the nanoemulsion may be poloxamer, polysorbate 20, nerolidol, 2-n-nonyl-1,3-dioxolane, urea, limonene, or a combination thereof, but is not limited thereto. In addition, any skin penetration promoter known as a skin penetration promoter can be used. Poloxamer may be preferably used as the skin permeation accelerator, and more preferably, any other skin permeation promoter may be used in combination with poloxamer. As such a combination, a combination of poloxamer and polysorbate 20 or a combination of poloxamer and limonene can be used. Skin permeation accelerators are generally used to increase the percutaneous absorption promotion of the active ingredient in the cosmetic field or transdermal medicines, but having a nanoemulsion composition according to the present invention can significantly enhance the percutaneous absorption promotion of the active ingredient.

The nanoemulsions according to the present invention are oil-in-water (o / w) emulsions with lipid particles in the nano-sized range, whereas the size of conventional lipid microspheres of conventional nanoemulsions is 100-200 nm, whereas It can have lipid microspheres of fine size.

The nanoemulsion according to the present invention is preferred because it can promote skin permeation for both water-soluble substances, fat-soluble substances, and protein drugs, and thus can be used for topical administration regardless of the physical properties of the active ingredient. In addition, when diluted in water, the state of the nanoemulsion can be maintained as it is, even in the diluted state can promote the skin penetration of the active ingredient without changing the size of the nanoemulsion particles. Therefore, even when the nanoemulsion is diluted in a cosmetic toner solution, essence, cream, etc., the nanoemulsion remains intact, and the skin permeation effect of the functional cosmetic ingredient is also excellent, which is particularly preferable for the manufacture of cosmetics. In addition, the nanoemulsion according to the present invention can be made by the selective skin permeation of the active ingredient with respect to the preservative in the preparation of the addition of a preservative. Therefore, there is an advantage that can reduce the side effects of the skin caused by the preservatives used indispensably in the manufacture of medicines or cosmetics. In addition, the nanoemulsion according to the present invention has a whitening effect on the skin of the phosphatidylcholine component in the lecithin used as a constituent thereof, and can give a whitening effect in addition to the effect of the main active ingredient. Therefore, there is a more advantageous advantage in the production of cosmetics for whitening. In addition, the nanoemulsion according to the present invention can be prepared by a simple mixing treatment without adding violent reaction conditions such as high pressure emulsification, and can be produced very simply and economically.

In another aspect of the invention, the invention is

Preparing a lecithin solution by dissolving lecithin in ethanol or butylene glycol;

Preparing a mixed solution by adding and mixing PEG-8 caprylic / capric glyceride and oil to the lecithin solution;

Adding water while stirring the mixture to form a nanoemulsion; And

Adding and mixing a skin permeation promoter to the nanoemulsion;

It provides a method for producing a nanoemulsion according to the present invention, characterized in that the active ingredient is dissolved in the oil or water according to the solubility of the active ingredient. The nanoemulsion composition according to the present invention may be prepared by simply mixing the components irrespective of the order of addition, but it is more efficient to form the nanoemulsion by preparing according to the same order as the above method.

The preparation method may be performed at room temperature, and the mixing may be performed by stirring, vortexing, or ultrasonication. When the active ingredient is fat-soluble, the active ingredient is dissolved in oil, and then the manufacturing method is performed. When the active ingredient is water-soluble, the active ingredient is dissolved in water, and then the manufacturing method may be performed.

The topical therapeutic nanoemulsion according to the present invention can be used in the manufacture of cosmetics or pharmaceuticals for topical administration.

Therefore, according to another aspect of the present invention provides a cosmetic comprising the nanoemulsion according to the present invention.

When used in the manufacture of cosmetics, the active ingredient in the nanoemulsion may include any functional cosmetic active ingredient, for example arbutin, vitamin C, adenosine, oil-soluble licorice, ceramide, botox-like peptide, pycnogenol, glucosyl hesperidin Or combinations thereof may be used.

In addition to the nanoemulsion, the cosmetic may further include an acceptable carrier, additive, preservative, and the like in the cosmetic field. A cosmetic may be prepared by diluting the nanoemulsion in a toner, essence or cream using a conventional toner, essence or cream as a carrier, or the nanoemulsion itself may be used as a cosmetic. The nanoemulsion according to the present invention is particularly advantageous in the manufacture of cosmetics that are used by diluting high formulation stability even when diluted. The additive may include acceptable additives commonly used in the cosmetic field, for example, persimmon leaf extract, willow bark extract, dianthus extract, root skin extract, rooibos extract, bark skin extract, herbal extracts or combinations thereof May be included. The preservative may include an acceptable preservative commonly used in the cosmetic field, for example, phenoxyethanol (PE), propyl paraben (PP), methyl paraben (MP), or a combination thereof may be used. . Preservatives may be added during the preparation of the nanoemulsions according to the invention or may be added even after the preparation of the nanoemulsions.

Further, according to another aspect of the present invention provides a pharmaceutical comprising a nanoemulsion according to the present invention.

When used in the manufacture of a medicament, the active ingredient in the nanoemulsion may be a pharmacologically active ingredient for topical administration, for example methotrexate, paclitaxel, cyclosporin A, vitamin D and its derivatives, urushiol and its derivatives, or Combinations of these may be used. In addition to the nanoemulsion, the medicament may further include additives or preservatives acceptable in the pharmaceutical field.

Cosmetics and pharmaceutical products including the nanoemulsion according to the present invention can be appropriately prepared by those skilled in the art based on conventional formulation techniques known in the art.

As described above, the nanoemulsion for topical administration according to the present invention can promote skin permeation for both water-soluble substances, fat-soluble substances, and protein drugs, and thus can be used for topical administration regardless of the physical properties of the active ingredient. In addition, when diluted in water, the state of the nanoemulsion can be maintained as it is, even in the diluted state can promote the skin penetration of the active ingredient without changing the size of the nanoemulsion particles. Therefore, even when the nanoemulsion is diluted in the cosmetic toner solution, essence and cream, the form of the nanoemulsion is maintained as it is, and the skin permeation effect of the functional cosmetic ingredient is also excellent, which is particularly preferable for the application of cosmetics. In addition, the nanoemulsion according to the present invention can be made by the selective skin permeation of the active ingredient with respect to the preservative by the addition of a preservative has the advantage of maximizing the effect of the active ingredient while reducing the side effects of the skin by the preservative. . In addition, the nanoemulsion according to the present invention has a whitening effect on the skin of the phosphatidylcholine component in the lecithin used as a constituent thereof, so that a whitening effect can be obtained in addition to the effect of the main active ingredient. In addition, the nanoemulsion according to the present invention can be prepared by a simple mixing process without adding violent reaction conditions such as high pressure emulsification, which has the advantage of being very simple and economical.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are only for the understanding of the present invention, and the scope of the present invention is not limited by them in any sense.

Example  1-9

Preparation of Arbutin-Containing Nanoemulsion-1

To prepare a nanoemulsion having a composition of Table 1. Specifically, the lecithin was dissolved in ethanol and then PEG-8 caprylic / capric glyceride (LAS) and isopropyl myristate (IPM) were added. After the mixture was thoroughly mixed, the nanoemulsion was prepared by adding an arbutin aqueous solution dissolved in distilled water with stirring. As the skin penetration promoter, poloxamer (PX), 2-n-nonyl-1,3-dioxolane (SEPA), nerolidol (NOR), poloxamer + NOR, poloxamer + urea, or poloxamer + poly Sorbate 20 (T20) was added to prepare nanoemulsions according to the invention, respectively. Thus prepared nanoemulsions of Examples 1 to 9 are shown in Table 1 below.

TABLE 1

Example  10-14

Preparation of Arbutin-Containing Nanoemulsion-2

To prepare a nanoemulsion having a composition of Table 2. Specifically, lecithin was dissolved in 1,3-butylene glycol (1,3-BG) and then PEG-8 caprylic / capric glyceride (LAS) and CC168 (cetyl caprylate) were added. After the mixture is thoroughly mixed, while stirring, an aqueous solution of arbutin dissolved in distilled water and some plant extracts known for whitening efficacy (persimmon leaf extract, dianthus extract, botan bark, willow bark extract) are added and stirred at room temperature for 30 minutes to form a nanoemulsion. Prepared. To this was added poloxamer + polysorbate 20 (Tween 20) as a skin penetration promoter to prepare a nanoemulsion according to the present invention, respectively. Thus prepared nanoemulsions of Examples 10 to 14 have a composition as shown in Table 2.

TABLE 2

Example 15-16

Preparation of High Concentration Arbutin-Containing Nanoemulsion-3

To prepare a nanoemulsion having the composition of Table 3. Specifically, the lecithin was dissolved in ethanol or butylene glycol, and then PEG-8 caprylic / capric glyceride (LAS) and isopropyl myristate (IPM) were added. After the mixture was thoroughly mixed, the nanoemulsion was prepared by adding an arbutin aqueous solution dissolved in distilled water with stirring. As the skin permeation accelerator, poloxamer + polysorbate 20 (Tween 20) was added to prepare nanoemulsions according to the present invention, respectively. Thus prepared nanoemulsion of Examples 15 to 16 has a composition as shown in Table 3.

[Table 3]

Example  17-18

Preparation of MTX-Containing Nanoemulsion-1

To prepare a nanoemulsion having a composition of Table 4. Specifically, the lecithin was dissolved in ethanol and then PEG-8 caprylic / capric glyceride (LAS) and isopropyl myristate (IPM) were added. After the mixture was thoroughly mixed, the nanoemulsion was prepared by adding MTX aqueous solution dissolved in distilled water with stirring. As the skin permeation accelerator, poloxamer + polysorbate 20 (Tween 20) was added to prepare nanoemulsions according to the present invention, respectively. Thus prepared nanoemulsion of Examples 17 to 18 has a composition as shown in Table 4.

TABLE 4

Example  19-22

Preparation of MTX-Containing Nanoemulsion-2

To prepare a nanoemulsion having a composition of Table 5. Specifically, the lecithin was dissolved in ethanol and then PEG-8 caprylic / capric glyceride (LAS) and isopropyl myristate (IPM) were added. After the mixture was thoroughly mixed, the nanoemulsion was prepared by adding MTX aqueous solution dissolved in distilled water with stirring. As a skin permeation accelerator, poloxamer + limonene (LM, Example 19), poloxamer + SEPA (PS, Example 20), poloxamer + nerolidol (PN, Example 21), poloxamer + linanol ( PL, Example 22), or Poloxamer + Polysorbate 20 (T20, Example 18) were added to prepare nanoemulsions according to the invention, respectively. Thus prepared compositions of the nanoemulsions of Examples 19 to 22 are shown in Table 5 below.

TABLE 5

Example  23

Preparation of MTX-Containing Nanoemulsion-3

Lecithin was dissolved in ethanol and 1,3-butylene glycol, and then PEG-8 caprylic / capric glyceride (LAS) and isopropyl myristate were added. After the mixture was completely mixed, distilled water and plant extract (Rooibos extract, Bark skin extract, Root skin extract, Willow skin extract), which dissolved MTX, were added while stirring, and stirred at room temperature for 30 minutes to prepare a nanoemulsion. Poloxamer + limonene was added here as a skin permeation promoter, and phenonip which is a preservative was added, and it stirred and completed. The content of each ingredient contained is as follows: MTX (1% by weight), lecithin (2% by weight), IPM (3% by weight), LAS (15% by weight), ethanol (5% by weight), 1,3 Butylenediglycol (5% by weight), Peel Extract (2% by weight), Rooibos Extract (3% by weight), Root Bark Extract (3% by weight), Willow Bark Extract (willow bark, 5% by weight), Poloxamer (1 wt.%), Limonene (1 wt.%), Phenonib (0.1 wt.%) As a preservative, distilled water (48.9 wt.%).

Example  24

Preparation of Cyclosporine A-Containing Nanoemulsions

Lecithin and cyclosporin A were dissolved in ethanol and then PEG-8 caprylic / capric glyceride (LAS) and isopropyl myristate were added. After the mixture was thoroughly mixed, distilled water was added while stirring, followed by stirring at room temperature for 30 minutes to prepare a nanoemulsion. Poloxamer + limonene was added here as a skin permeation promoter, and it was completed by stirring. The content of each ingredient contained above is as follows: cyclosporin A (1% by weight), lecithin (2% by weight), IPM (3% by weight), LAS (20% by weight), ethanol (10% by weight), poloc Summer (1% by weight), limonene (1% by weight), distilled water (62% by weight).

Example  25

Preparation of Antioxidant Pycnogenol-Containing Nanoemulsion

Lecithin was dissolved in 1,3-butylene glycol and then PEG-8 caprylic / capric glyceride (LAS) and CC168 (cetyl caprylate) were added. After the mixture was thoroughly mixed, the pycnogenol powder was added with stirring, distilled water was added, and stirred at room temperature for 30 minutes to prepare a nanoemulsion. Poloxamer + Tween20 was added to this as a skin permeation promoter, and it was completed by stirring. The content of each component contained is as follows: pycnogenol (2% by weight), lecithin (4% by weight), IPM (6% by weight), LAS (25% by weight), 1,3-butylene diglycol (10 Weight percent), poloxamer (2 weight percent), Tween20 (2 weight percent), distilled water (49 weight percent).

Example  26-29

Preparation of Nano Emulsion Containing EAE (Ethyl ascorbic ether)

Lecithin was dissolved in ethanol or 1,3-butylene glycol, then PEG-8 caprylic / capric glyceride (LAS) was added and isopropyl myristate or CC168 was added. After the mixture was thoroughly mixed, an aqueous solution of ethyl ascorbic ether (EAE) dissolved in distilled water was added while stirring, followed by stirring at room temperature for 30 minutes to prepare a nanoemulsion. Poloxamer and polysorbate 20 (Tween 20) were added thereto as a skin permeation promoter, and completed by mixing.

The content of each component contained in the preparation of the nanoemulsion is shown in Table 6 below.

TABLE 6

Example 30-32

Preparation of EGF-Containing Nanoemulsions

Lecithin was dissolved in 1,3-butylene glycol or ethanol and then PEG-8 caprylic / capric glyceride (LAS) was added and CC168 or IPM was added. After the mixture was thoroughly mixed, an aqueous solution of EGF (epidermal growth factor) dissolved in distilled water was added thereto while stirring, and stirred at room temperature for 30 minutes to prepare a nanoemulsion. Poloxamer and polysorbate 20 (Tween 20) were added thereto as a skin permeation promoter, and the mixture was stirred. In Example 32 adenosine powder was added to the mixture before adding the EGF solution.

The content of each component contained is shown in Table 7.

TABLE 7

Experimental Example  One: in vivo  Skin Permeation Experiment

The nanoemulsion prepared in Example 1-3 itself was applied to the inner region of the arm of the volunteer, or the nanoemulsion was experimented by diluting and applying to the cosmetic (toner). After 1 hour of application, tape stripping was performed with Transpore ^3M . Each tape was placed in a counting vial, stirred with 3 mL of PBS buffer overnight and vigorously vortexed to extract arbutin and analyzed by HPLC. As a control, an aqueous arbutin solution (control group 1) and a nanoemulsion (control group 2) without adding a skin permeation accelerator were used. The results are shown in Table 8 below.

TABLE 8

Experimental Example 2: in vitro skin permeation experiment

(1) in vitro skin permeation experiment of arbutin-containing nanoemulsion

In vitro skin permeation experiments were performed on Example 8 containing poloxamer and polysorbate 20 as skin permeation promoters. The skin at the back and belly of the hairless mouse was used in the experiment. Specifically, the skin was prepared by cutting the scissors near the tail of the mouse with a suitable size. After removing the fat present in the skin, the skin was placed in a Franz diffusion cell and the nanoemulsion was placed on the skin. Over time, 0.6 ml was taken from the diffusion cell, and the experiment was repeated by replenishing 0.6 ml. After separating skin after 12 or 23 hours, wash skin thoroughly with distilled water and PBS buffer, homogenize for 3 minutes by adding 3 ml of PBS buffer, centrifuge and take supernatant Analyzed. Quantification of arbutin that passed through the skin in addition to arbutin present in the skin was determined by HPLC method.

As a control, the same concentration of aqueous arbutin solution (control group 1) and nanoemulsion (control group 2) without addition of a skin permeation accelerator were used. The results are shown in FIG.

As can be seen from the results of Figure 1, in the case of the nanoemulsion according to the present invention it can be seen that the skin permeation time is shortened and the amount of arbutin absorbed percutaneously increases. On the contrary, in case of the control group 2, which is a nanoemulsion in which no skin permeation accelerator is present, it can be seen that the permeation rate of arbutin is significantly lower than that of the nanoemulsion of Example 8, although it promotes skin permeation rather than an aqueous arbutin solution (control group 1).

In the measurement of the content of arbutin remaining in the skin, arbutin is the most abundant in the stratum corneum (control 1), but in the epidermis and dermis, the arbutin content is increased in the case of the nanoemulsion of control 2 and Example 8 It showed an aspect. From these results, it can be seen that the nanoemulsion according to the present invention improves skin penetration of arbutin by about 20 times.

(2) 14 wt% arbutin Nanoemulsion  When diluted in in vitro  Skin Permeation Experiment

In the skin permeation promoting effect of the nanoemulsion according to the present invention, in order to confirm the effect in the cosmetic prepared by diluting, the 14 wt% arbutin-containing nanoemulsion prepared in Example 15 was diluted to 2.1 wt% containing arbutin. Next, the skin permeation experiment was performed in the same manner as the in vitro skin permeation experiment. Specifically, 15% by weight of the nanoemulsion and 85% by weight of cosmetics (toner, cream, essence) was mixed to perform a skin permeation experiment. As cosmetics used for dilution, the toner is 1,3-BG (3% by weight), glycerin (2% by weight), ethanol (5% by weight), methylparaben (1.1% by weight), phenoxyethanol (0.15% by weight), PEG-40 hydrogenated castor oil (0.4 wt%), fragrance (0.1 wt%), distilled water (89.25 wt%) were used, and the essence was 1,3-BG (5 wt%). %), Glycerin (4% by weight), hydroxy ethyl cellulose (0.04% by weight), carbopol (0.1% by weight), methylparaben (0.1% by weight), phenoxyethanol (0.16% by weight), ethanol (5% by weight %), Dimethicone (0.5 wt%), PEG-40 hydrogenated castor oil (0.5 wt%), triethanolamine (0.1 wt%), fragrance (0.15 wt%) and distilled water (84.36 wt%) Cream was used, BG (5% by weight), Glycerin (4% by weight), Caibopol (0.3% by weight), Methylparaben (0.15% by weight), Femoethanol (0.1% by weight), Stearic acid (1.5% by weight) ), Glyceryl monostearate (of 0.8 %), Lecithin (0.6% by weight), jojoba oil (3% by weight), mineral oil (5% by weight), dimethicone (1% by weight), sacyl alcohol (0.8% by weight), butyrate hydroxytonluene (0.03 Wt%), Butylparaben (0.1 wt%), Propyl paraben (0.1 wt%), Vaseline (0.8 wt%), Multiwax (0.5 wt%), Vitamin E (0.5 wt%), Triethanolamine (0.25 wt%, And distilled water (75.47% by weight), in order to test the effect of the skin permeation accelerator itself, an aqueous solution containing the skin permeation accelerator and arbutin under the same conditions as the diluent of Example 15 in the toner (control 2). And a comparative experiment with an aqueous solution containing only arbutin (control group 1).

The results are shown in FIG.

According to the results of FIG. 2, the nanoemulsion according to the present invention was shown to significantly promote skin permeation of arbutin even upon dilution, and showed a significantly higher skin permeation effect compared to the added arbutin aqueous solution alone.

In addition to the toner, in the case of the essence and the cream, the skin penetration of arbutin was significantly increased in the nanoemulsion-containing essence and the cream compared to the control.

(3) In vitro skin permeation test when preservative is added to arbutin-containing nanoemulsion

In vitro skin permeation experiment was performed on the nanoemulsion of Example 12 in the same manner as the in vitro skin permeation experiment. However, in addition to the percutaneous absorption of arbutin, preservatives were also added by adding a preservative.

When preservatives (methylparaben (MP), propylparaben (PP), phenoxyethanol (PE)) are added during the preparation of the nanoemulsion of Example 12 (when oil and surfactant are added) (Nano-BE ) And the addition after the preparation of the nanoemulsion (Nano-BF) were compared with the general formulation (the toner) as a control. The results are shown in FIG.

In Figure 3 "receptor" refers to the area that passed through the skin, and refers to the amount of drug present in the buffer solution under the skin.

According to the results of FIG. 3, in the case of the control group, arbutin showed little skin permeation, and in the case of the nanoemulsion of Example 12, the arbutin did not only penetrate the skin well but also increased the amount remaining in the skin. These results indicate that, regardless of the addition of preservatives, the nanoemulsions according to the invention promote skin penetration of the active ingredient. The amount of arbutin permeated by the skin was increased more than 10 times compared to the control group, but the amount of arbutin remaining in the skin did not show much difference from the control group. This is believed to be due to the limitation of the amount accumulated in the skin because the thickness of the mouse skin is very thin.

Separately, when the phenoxyethanol (PE), propyl paraben (PP), or methyl paraben (MP) is added as an antiseptic agent in the experiment, the skin permeation experiment was performed in the same manner as the in vitro skin permeation experiment, The amount of preservative (skin content) present in the skin and the amount of preservative (receptor content) passed through the skin were measured, respectively. The results are shown in FIGS. 4 and 5 and Table 9 below.

TABLE 9

According to the results of FIGS. 4, 5, and Table 9, when comparing the skin permeation of the preservative in the nanoemulsion formulation according to the present invention with other general formulations, the case of the general formulation (control), unlike the arbutin, preservatives permeated into the skin It can be seen that the content of is measured much higher. These results were unpredictable and showed the same pattern as the result of repeated experiments. That is, the nanoemulsion preparation according to the present invention exhibits a selective skin permeation aspect that promotes skin penetration of arbutin but inhibits skin penetration of preservatives.

Experimental Example  3: whitening effect experiment

A whitening test was performed on the nanoemulsion containing 2 wt% arbutin prepared in Examples 8 and 12 (FIG. 7). As a control, the same concentration of aqueous arbutin solution (Control 1, FIGS. 6 and 7) and Control 2 used in FIG. 7 were compared using a general toner containing 2 wt% arbutin (Control 2, FIG. 7). The general toner used in the control 2 of Figure 7 was to contain 2% by weight arbutin, 10% by weight 1,3-butylene glycol, 5% by weight additives (botanpi, persimmon leaves, dianthus, willow bark extract).

Two cell lines were used to test the whitening effect. The whitening efficacy was measured using non-tumorigenic cells (melan-a), a cell line before fully differentiated into cancer cells, and B16 melanoma cell line, which can cause metastasis. Melan-a cell line is closer to the normal human melanocytes.

After culturing the cells in 96 wells, the amount of melanin produced externally while adding Example 8 or 12, control 1 or 2 to the cells in 2-fold dilution and continuing incubation for 4-5 days at 37 ℃, 5% by weight carbon dioxide environment Was measured by absorbance.

The results are shown in FIGS. 6 and 7.

According to the whitening activity results for Melan-a cells of FIG. 6, the aqueous solution of arbutin, which is the control group 1, showed weak whitening activity at a very high concentration, whereas the nanoemulsion of the present invention showed much higher whitening activity than the control at a very low concentration. It was.

According to the results of FIG. 7, the aqueous solution of arbutin, which is the control group 1, showed weak whitening activity at very high concentrations, whereas the nanoemulsion of the present invention showed very high whitening activity even at low arbutin concentrations. The general toner containing the additive known to have a whitening effect (control 2) showed a high whitening activity compared to the control 1, but showed a significantly lower whitening activity than the nanoemulsion of the present invention.

Experimental Example  4: Determination of the stability of arbutin

Elapsed time (2 weeks, 4 weeks, 8 weeks, and 4 weeks) for storing the 14% by weight arbutin-containing nanoemulsions of Examples 15 and 16 as they were stored at room temperature and 43 degrees or diluted toner to 2% by weight arbutin. Stability test was performed by observing precipitation and color change. As a control, an aqueous arbutin solution (A) of 14% by weight was used.

In FIG. 8, the photograph of each sample after 2 weeks, 4 weeks, 8 weeks, and 4 months after 43 degreeC is shown. According to the results of FIG. 8, when the color change was observed at 43 ° C., in the case of the aqueous arbutin solution (control group A), severe precipitation and browning were remarkable, whereas in Example 15 (B) and Example 16 (C) Emulsions (B, C) showed little precipitation and color change. Therefore, it can be seen that the nanoemulsion according to the present invention significantly increases the stability of arbutin itself.

The stability was observed by diluting the 14 wt% arbutin nanoemulsion in toner to 2 wt% arbutin and then measuring the particle change of the nanoemulsion while storing at 4, room temperature and 43 ° C.

According to FIG. 9, it was confirmed that when the nanoemulsion according to the present invention was diluted in a cosmetic toner, particle size change hardly occurred for 17 weeks, and thus, the nanoemulsion according to the present invention showed very high formulation stability.

Experimental Example 5 Comparison of Skin Permeation of MTX-Containing Nanoemulsion

The in vitro skin permeation experiment was performed on the methotrexate (MTX) -containing nanoemulsion of Example 17 and MTX aqueous solution as a control. Before the in vitro skin permeation experiment, the particle size of the nanoparticles was analyzed. Particle size was measured by laser light scattering method, the nanoemulsion was measured by diluting with distilled water (more than 10 times), Nicomp 370, Particle Sizing System. The size of the particles was determined by volume distribution. As a result of the measurement, the nanoemulsion had an average particle size of about 15-30 nm. This particle size was found to be such that the nanoemulsion is transparent.

The methotrexate (MTX) -containing nanoemulsion of Example 17 and the control MTX aqueous solution was tested in the same manner as in vitro skin permeation experiment of Experimental Example 2.

The results of comparing MTX skin penetration after 24 hours are shown in FIG. 10. According to FIG. 10, the MTX did not pass through the control group, and the MTX-containing nanoemulsion promoted skin penetration 20 times more than the control group.

The amount of MTX remaining in the skin was also found to be highest in the nanoemulsion. The extent to which it remained on the skin was similar to that through the skin.

Experimental Example  6: MTX  According to concentration Of nanoemulsion  Skin penetration comparison

Reported difference in skin permeability according to concentration of MTX (reported increase in skin permeability above 0.3 wt%, (MJ Alvarez-Figueroa, MB Delgado-Charro, J. Blanco-Mendez, Passive and iontophorwtic transdermal penetration in methotrexate.Int. J. Pharm. 212: 101-107, 2001).

Skin permeation experiments were performed on the MTX-containing nanoemulsions of Example 17 (MTX concentration 0.2 wt%) and 18 (MTX concentration 0.5 wt%) in the same manner as in vitro skin permeation test of Experimental Example 2. As a control, the MTX aqueous solution corresponding to each concentration was prepared and tested.

The results are shown in FIG.

According to the results of FIG. 11, the nanoemulsion showed better skin permeation than the control group, and it was confirmed that skin permeation was also promoted as the concentration increased. As the concentration increased, skin permeation was promoted in both the control group and the nanoemulsion. This is not an increase of 2.5 times compared to 0.2%, but more increases. In the case of 0.5 wt% MTX containing nanoemulsion, about 6 wt% (about 300 mg) passed after 24 hours.

Experimental Example  7: according to the type of skin penetration accelerator MTX Of nanoemulsion  Skin penetration comparison

Examples 18 (poloxamer + polysorbate 20, PT), 19 (poloxamer + limonene, LM), 20 (poloxamer + SEPA, PS), 21 (polox) prepared using various combinations of skin penetration promoters Skin permeation experiments were performed on the MTX-containing nanoemulsions prepared in Samer + nerolidol, PN) and 22 (poloxamer + linanol, PL) in the same manner as in vitro skin permeation test of Experimental Example 2. As a control, an aqueous solution of 0.5 wt% MTX concentration was prepared and tested.

The results are shown in FIG.

According to FIG. 12, the highest skin permeation promoting effect was found in the nanoemulsion (LM) containing limonene with poloxamer, followed by the emulsion (PT) containing polysorbate 20 together with poloxamer. Next, the skin permeation promoting effect was shown in the order of excellent, LM> PT> PS> PL> PN> control group. Deposition order was similar, but the amount of MTX in the PT increased more than LM. When the amount of skin remaining in high order, PT> LM> PS> PN> PL> control was found.

Experimental Example  8: MTX Of nanoemulsion  Treatment effect verification

The MTX-containing nanoemulsion of Example 23 was applied to the skin of psoriasis patients to confirm the therapeutic effect. It was applied only to the psoriasis area of one arm of the psoriasis patient, not applied to the other arm, and the results were compared. The nanoemulsion was applied once a day for one month, and then each affected area was observed. A photograph taken of the affected area a month after the treatment is also shown in FIG. 13. According to the results of FIG. 13, a significantly improved effect of the psoriasis site was observed in the affected areas to which the MTX-containing nanoemulsion of Example 23 was applied.

Experimental Example  9: EAE Of nanoemulsion  Skin Permeation Experiment

In vitro skin permeation experiment for the EAE-containing nanoemulsion of Examples 26 and 27 was carried out in the same manner as in vitro skin permeation experiment of Experimental Example 2. As a control, 5% by weight of an EAE aqueous solution was used. The results are shown in FIG.

As shown in FIG. 14, Examples 26 and 27 showed very significant skin permeation promoting effects compared to the control group, but Example 27 showed the best effect.

Experimental Example  10: cyclosporin A Of nanoemulsion  Skin penetration experiment

In vitro skin permeation experiment for the cyclosporin A-containing nanoemulsion of Example 24 was carried out in the same manner as in vitro skin permeation experiment of Experimental Example 2. The nanoemulsion of Example 24 was diluted 1: 1 with distilled water to be 0.5% by weight of cyclosporin A. As a control, a 50% ethanol solution containing 0.5% by weight of cyclosporin A was used. As a result, in the 50% ethanol solution, 7.7 μg of cyclosporin A was permeated to the skin, and in the case of nanoemulsion, 30 μg was permeated to the skin. Nanoemulsion showed about 4 times more skin penetration promoting effect than 50% ethanol solution.

From the above results, it can be seen that the nanoemulsion promotes skin penetration of water-soluble and fat-soluble drugs.

Experimental Example  11: EGF Of nanoemulsion  Skin Permeation Experiment

In vitro skin permeation experiment for the EGF-containing nanoemulsion of Examples 30 to 32 was carried out in the same manner as in vitro skin permeation experiment of Experimental Example 2. As a nanoemulsion containing EGF (0.01% by weight) and a control, a PBS solution (control 1) and 0.01% by weight of an aqueous solution of EGF (control 2) were used.

The results are shown in FIG.

According to FIG. 15, in the control group, no EGF was observed at the receptor (site passing through the skin), but skin permeation occurred in the EGF nanoemulsion of Example 31. In the case of the aqueous solution of EGF, which is the control 2, the EGF band of the EGF nanoemulsion of Example 31 was darkly observed, although not observed in the EGF measurement strip as in the control 1. From this, it can be seen that EGF in the nanoemulsion passes through the skin of hairless mice, which means that when applied to humans, epidermis and dermis can be reached.

In addition, after the end of the skin permeation experiment of control 2 and nanoemulsion (Example 31), the solution of the receptor portion was added to the fibroblasts to measure the activity of EGF. Receptor solution of control 2 and nanoemulsion was added to the fibroblast culture. Fibroblasts were cultured and diluted in medium at a concentration of 2 × 10 ⁴ / ml, and then aliquoted at 135 μl / well into 96 well plates, and 10 ul of the receptor solution of control 2 and nanoemulsion was added to 96 well plates. After incubation for 3 days at 5% by weight carbon dioxide, and observed with an optical microscope (100X) is shown in Figure 15 together. According to FIG. 15, only the nanoemulsion group of Example 31 was found to have a cell proliferation effect. These results indicate that the nanoemulsion according to the present invention not only promotes skin permeation of the protein but also maintains the activity of the protein without degrading the protein during skin permeation, which can be used substantially in the formulation of the protein. It is an important result. From these results, it can be seen that the nanoemulsion according to the present invention is a skin permeation promoting system capable of passing not only low molecular weight substances such as arbutin, MTX, and EAE but also high molecular weight substances such as proteins.

1 is a graph showing the results of in vitro skin permeation experiment through resected skin of hairless mice containing 2% by weight of arbutin-containing nanoemulsion according to the present invention.

Figure 2 is a graph showing the results of in vitro skin permeation through the resected skin of hairless mice for diluting the 14% by weight arbutin-containing nanoemulsion according to the present invention to 2% by weight compared to the control.

FIG. 3 shows the case of adding a preservative to a 2% by weight arbutin-containing nanoemulsion according to an embodiment of the present invention (Nano-BE) and after the preparation of the nanoemulsion (Nano-BF). The results of in vitro skin permeation through resected skin of nasal and hairless mice were compared with the control group.

4 and 5 are hairless for the case of adding phenoxyethanol (PE), propyl paraben (PP), methyl paraben (MP) as a preservative to the 2% by weight arbutin-containing nanoemulsion according to an embodiment of the present invention, respectively This is a graph showing the results of measuring the amount of preservatives present in each of the skin and the receptor by performing in vitro skin permeation experiments through excised skin of mice.

6 is a graph showing the results of measuring the degree of inhibition of melanin formation using a melan-a cell line for the nanoemulsion containing various concentrations of arbutin according to an embodiment of the present invention compared to a control.

7 is a graph showing the results of measuring the degree of inhibition of melanin formation using a B16 melanoma cell line for the nanoemulsion containing various concentrations of arbutin according to an embodiment of the present invention compared to the control.

8 is a 14 wt% arbutin aqueous solution (A) according to an embodiment of the present invention, 14 wt% Arbutin-containing nanoemulsion (B, C) is photographed the change in appearance over time.

FIG. 9 is a graph showing the change in the size of nanoemulsion particles with time at room temperature and 43 ° C. after diluting a 14% by weight arbutin-containing nanoemulsion with toner to contain 2% by weight arbutin according to an embodiment of the present invention. And a graph shown in comparison with the control (toner).

FIG. 10 is a graph showing the results of in vitro skin permeation experiments through resected skin of hairless mice on MTX-containing nanoemulsions according to an embodiment of the present invention compared to a control group.

FIG. 11 is a graph showing the results of in vitro skin permeation experiments through resected skin of hairless mice on 0.2% by weight MTX-containing nanoemulsion and 0.5% by weight MTX-containing nanoemulsion in accordance with an embodiment of the present invention.

Figure 12 shows the results of in vitro skin permeation through resection skin of hairless mice on nanoemulsions containing 0.5% by weight MTX and a combination of various skin penetration enhancers according to one embodiment of the present invention at a concentration of 0.5% by weight of MTX It is a graph compared with the control of the aqueous solution.

Figure 13 is applied to the MTX-containing nanoemulsion according to an embodiment of the present invention only once in the psoriasis region of one arm of the psoriasis patient once a day, the treatment does not apply to the psoriasis region of the other arm after a month after This picture was taken.

Figure 14 is a graph showing the results of in vitro skin permeation through the resected skin of hairless mice on the EAE-containing nanoemulsion according to an embodiment of the present invention compared to the control of an aqueous solution of 5% by weight EAE.

Figure 15 shows the effect of promoting the skin permeation of EGF through the excised skin of hairless mice using a control group (1), a phosphate buffer solution containing no EGF, a control group (2) and an EGF solution according to one embodiment of the present invention. It was compared (left), the EGF solution of the control (2) and nanoemulsion according to one embodiment of the present invention was added to the fibroblast culture to compare the activity of EGF (right).

<Description of Symbols in Drawing>

Stratum corneum: drug content in the stratum corneum

Skin: Drug content present in skin

Receptor: drug content present in the receptor

-Nano-BE: Nanoemulsion pretreated with preservative

Nano-AF: nanoemulsion after-treatment with preservative

PE: phenoxyethanol

MP: methyl paraben

-PP: propyl paraben

Claims (13)

An activity comprising 1-10 parts by weight of oil, 5-40 parts by weight of PEG-8 caprylic / capric glyceride, 0.5-10 parts by weight of lecithin, 0.5-10 parts by weight of skin penetration promoter, and 20-90 parts by weight of water Component-containing nanoemulsions for topical administration. The nanoemulsion of claim 1, further comprising an alcohol selected from the group consisting of ethanol, butylene glycol, isopropyl alcohol, glycerol, and combinations thereof. The method of claim 1, wherein the oil is isopropyl myristate, medium chain triglycerides, hexyldecanol, cetyl caprylate, jojoba oil, mineral oil, soybean oil, evening primrose oil, camellia oil, Emu oil, borage oil, Nanoemulsion, characterized in that the pumpkin seed oil, or a combination thereof. The nanoemulsion according to claim 1, wherein the lecithin has a phosphatidylcholine content of 50% by weight or more. The nanoemulsion of claim 1, wherein the skin penetration enhancer is poloxamer, polysorbate 20, nerolidol, 2-n-nonyl-1,3-dioxolane, urea, limonene, or a combination thereof. . 5. The nanoemulsion of claim 4 wherein said skin permeation promoter is a combination of poloxamer and other skin permeation promoters. 6. The nanoemulsion of claim 5, wherein the skin penetration enhancer is a combination of poloxamer and polysorbate 20 or a combination of poloxamer and limonene. The nanoemulsion according to claim 1, which is diluted in a medium which is pharmaceutically or cosmetically acceptable. Preparing a lecithin solution by dissolving lecithin in ethanol, butylene glycol, isopropyl alcohol, or glycerol; Preparing a mixed solution by adding and mixing PEG-8 caprylic / capric glyceride and oil to the lecithin solution; Adding water while stirring the mixture to form a nanoemulsion; And Adding and mixing a skin permeation promoter to the nanoemulsion; The method for preparing a nanoemulsion according to any one of claims 1 to 8, wherein the active ingredient is dissolved in the oil or water depending on the water solubility of the active ingredient. Cosmetics comprising the nanoemulsion according to any one of claims 1 to 8. The cosmetic according to claim 10, wherein the active ingredient is arbutin, vitamin C, adenosine, peptide, cytokine, growth factor, ceramide, pycnogenol, herbal extract, or a combination thereof. A pharmaceutical product comprising the nanoemulsion according to any one of claims 1 to 8. 13. The pharmaceutical product according to claim 12, wherein the active ingredient is methotrexate, paclitaxel, cyclosporin A, echonazol, fluconazole, vitamin D derivatives, or a combination thereof.

Images